Richard Conway RichardPAConway
4 years ago
Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortality depending on exact mutation. Looking forward to hearing more about this at Plenary session III today #ACR21 @RheumNow https://t.co/R3gXpxOfSk
David Liew drdavidliew
4 years ago
Baricitinib for *relapsing* GCA (Th1+Th17)
w abbreviated steroid wean (15-22w)
Despite being tougher to treat:
100% off steroids at 24w
93% off steroids at 52w
no ischemic Sx
promising as another GCA Rx option!
(post-cessation 4pts flared)
@MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk
Aurelie Najm AurelieRheumo
4 years ago
It is #ACR21, but it is also #COP26Glasgow 🌎! What can we do for climate as physicians? "Our job is to make changes" Strong message for #ClimateAction from Dr Paul Dellaripa during his talk at the climate, pollution and IRMDs study group session @RheumNow https://t.co/GWxpzYD3lg
David Liew drdavidliew
4 years ago
"GCA is not a single, monolithic disease"
- Christian Dejaco, rightfully asking why we don't stratify treatment/trials in GCA
#ACR21 PMR/GCA Study Group @RheumNow @Sarah_L_Mackie @profbdasgupta @EBRheum @RichardPAConway @SattuiSEMD @drceowen
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With multiple JAK inhibitors available in the United States (tofacitinib, baricitinib, and upadacitinib), patients who fail one treatment option have the ability to switch to another agent or change to biologic therapy.
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Eric Dein ericdeinmd
4 years ago
#ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u
Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail?
https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
Eric Dein ericdeinmd
4 years ago
#ACR21 Rheum Pearls and Secrets
Not all (or most) ulcers is Behcet's! Here's a great approach to use in clinic. Jason Kolfenbach: "Sometimes, taking off the mask is worth it"
@Rheumnow https://t.co/OEBgf1eFhd


Poster Hall